Brief: Edgewise Therapeutics Inc On Track To Deliver Full 12-Week Part D Readout In 2Q 2026 And Phase 3 Start In 4Q 2026
24/12/2025 13:06
Dec 24 (Reuters) - Edgewise Therapeutics Inc EWTX.O: EDGEWISE THERAPEUTICS INC: ON TRACK TO DELIVER FULL 12-WEEK PART D READOUT IN 2Q 2026 AND PHASE 3 START IN 4Q 2026 EDGEWISE THERAPEUTICS INC - COMPLETES PHASE 2 PARTS B AND C OF CIRRUS-HCM EDGEWISE THERAPEUTICS INC - EDG-7500 WELL TOLERATED WITH NO SIGNIFICANT LVEF REDUCTIONS Source text: ID:nPn5nLldTa Further company coverage: EWTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Edgewise Therapeutics
See all newsBrief: Edgewise Therapeutics Doses First Patient In Phase 2 Equinox-Hfpef Trial Of Edg-15400
Edgewise Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Edgewise Therapeutics Q2 net loss widens on higher expenses
Brief: Edgewise Therapeutics Q2 Operating Income USD -61.943 Million
U.S. STOCKS ON THE MOVE-RBB Bancorp, Roblox, Open Lending